Published in Cancer Weekly, September 23rd, 2003
Jijun Wu, chairman of Eternal Technologies, said, "The technology filed in this patent is our biotech division's most significant development to date. The patent relates to the interaction of the mutative gene of enterotoxin A with the ScFv (Single-Chain Variable-Fragment) gene and the application of the fused protein in the immunotherapy for tumors."
Chairman Wu continued, "Cancer therapies require antitumor effects that are either delivering potentially toxic agents to all...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.